Description and Brand Names
Drug information provided by: Merative, Micromedex®
US Brand Name
- Hercessi
Descriptions
Trastuzumab-strf injection is used together with other cancer medicines (eg, doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, or docetaxel and carboplatin) or used alone following anthracycline-based therapy to treat HER2-overexpressing node-positive or node-negative (ER/PR negative or with one high risk feature) breast cancer.
Trastuzumab-strf injection is also used to treat HER2-overexpressing metastatic (cancer that has spread) breast cancer in patients who have received one or more chemotherapy treatments. It is also used together with paclitaxel for the first-line treatment of HER2-overexpressing metastatic breast cancer.
Trastuzumab-strf injection is also used together with cisplatin and capecitabine or 5-fluorouracil to treat HER2-overexpressing metastatic (cancer that has spread to other parts of the body) stomach caner called gastric or gastroesophageal junction (GEJ) adenocarcinoma in patients who have not previously received treatment.
Trastuzumab-strf prevents the growth of some tumors that produce extra amounts of a certain substance known as the HER2 protein. It should only be used in patients whose tumors have been shown to produce extra amounts of this protein (HER2 overexpression).
Trastuzumab-strf is a monoclonal antibody. It interferes with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal body cells may also be affected by trastuzumab-strf, other effects will also occur. Some of these may be serious and must be reported to your doctor.
This medicine is to be given only by or under the immediate supervision of your doctor.
Portions of this document last updated: June 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.